Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Actual. SIDA. infectol ; 31(112): 36-43, 20230000. graf, tab
Article in Spanish | BINACIS, LILACS | ID: biblio-1451840

ABSTRACT

Introducción: La incidencia de Enterobacterales resistentes a carbapenemes (ERC) se elevó en la última década, y en especial durante la pandemia de COVID-19. Objetivo: Conocer el perfil de resistencia antimicrobiana, así como la frecuencia y tipo de carbapenemasas presen-tes en los aislamientos de ERC en un hospital regional.Materiales y métodos: Estudio epidemiológico, observa-cional y retrospectivo. Incluyó ERC aislados en muestras clínicas durante 2021 en un hospital regional de Santa Fe, Argentina. El cálculo de la incidencia (aislamientos/pacien-tes-día) e intervalo de confianza 95% (IC 95%), y las pruebas estadísticas se realizaron con OpenEpi.Resultados: 348 ERC aislados (11,9 aislamientos/1000 pacientes-día; IC95% 10,7-13,2). La incidencia se correla-cionó con los casos de COVID-19 (rho=0,874, p<0,001) y fue a expensas de la Unidad de Cuidados Intensivos (76,4%). El principal ERC aislado fue Klebsiella pneumoniae (71,4%, n=260). KPC fue el principal mecanismo de resistencia (61,2%). Se aislaron dos doble productores de carbapene-masas. La tasa global de resistencia a los antibióticos no betalactámicos evaluados fue superior en Klebsiella pneu-moniae que en el resto de los aislamientos resistentes a carbapenemes (60,6% vs. 38,5%, p<0,001). En KPC hubo mayor resistencia a colistin (44,6% vs. 23,9%, p=0,001) y menor a amikacina (23,9% vs. 72,6%, p<0,001).Conclusión: Frente a las escasas opciones terapéuticas en infecciones por ERC se destaca la importancia de conocer los mecanismos de resistencia implicados y la epidemiología local


Introduction: The incidence of carbapenem-resistant Enterobacterales (CRE) rose in the last decade, and especially during the COVID-19 pandemic.Objective: To identify the antimicrobial resistance profile, as well as the frequency and type of carbapenems that were present in CRE isolations in a tertiary care hospital.Materials and methods: Epidemiological, observational and retrospective study. It included CRE isolated in clinical samples during 2021 in a tertiary care hospital in Argentina. Incidences (isolations/patients-day), confidence intervals of 95% (CI 95%) and statistical comparisons were made with OpenEpi.Results: 348 CRE were isolated (11.9 isolations/1,000 patients-day, IC95% 10.7-13.2). Incidence correlated to COVID-19 cases (rho=0.874, p<0.001). Most isolations were from the Intensive Care Unit (76.4%) and the from respiratory samples (27.6%, n=96) and blood cultures (24.4%, n=92). The main isolated CRE was Klebsiella pneumoniae (71.4%, n=260), with a general carbapenem resistance of 53.4%. KPC was the main resistance mechanism (61.2%). Two double carbapenemase-producing Enterobacterales were isolated. Klebsiella pneumoniae presented a higher overall resistance rate to non-betalactam antibiotics (60.6% vs 38.5%, p<0.001). Among CRE, a higher colistin resistance rate was found in KPC isolations (44.6% vs 23.9%, p=0.001) and lower resistance to amikacin (23.9% vs 72.6%, p<0.001).Conclusion: The difficulty in the selection of antibiotic regimens for CRE forces the treating physicians to put emphasis on the knowledge of resistance mechanisms to optimize them


Subject(s)
Humans , Male , Female , Drug Resistance, Microbial , Epidemiology , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Hospitals, Public
2.
Actual. SIDA. infectol ; 27(101): 74-81, 20191200. fig
Article in Spanish | LILACS, BINACIS | ID: biblio-1353811

ABSTRACT

Introducción: La emergencia de enterobacterias productoras de carbapenemasas en el ámbito hospitalario representa un verdadero problema de salud pública mundial. Las carbapenemasas son enzimas que producen resistencia a los antibióticos carbapenémicos, teniendo un directo impacto en la disponibilidad de alternativas terapéuticas. En Argentina, a partir de 2013 han emergido carbapenemasas tipo-NDM (Nueva Delhi Metalo-ß-lactamasa, MßL), que constituyen una resistencia emergente a nivel global. Objetivo: Reportar el primer aislamiento clínico de enterobacteria portadora de NDM en nuestra institución. Materiales y métodos: El aislamiento estudiado fue recuperado de una muestra ósea de un paciente adulto. La identificación bacteriana y los ensayos de susceptibilidad antibiótica se realizaron mediante metodología manual y sistema automatizado Vitek 2C (Biomérieux). La detección y caracterización de carbapenemasas se efectuó por ensayos fenotípicos y moleculares. Resultados: Los ensayos revelaron que el aislamiento, tipificado como Citrobacter freundii, es productor de carbapenemasa tipo NDM. Resultó sensible a aztreonam, colistina y fosfomicina. No se detectó fenotípicamente la presencia de beta lactamasas de espectro extendido. Discusión: Se reporta el primer aislamiento de enterobacteria productor de MßL tipo-NDM en nuestro nosocomio, siendo multirresistente, con escasas alternativas terapéuticas. Dado que la presencia de este tipo de aislamiento es considerado de alto riesgo, se requiere un monitoreo activo de este mecanismo de resistencia y la instauración de medidas de control adecuadas para hacer frente a la amenaza que suponen


Introduction: the emergence of carbapenemase-producing Enterobaceriaceae in the hospital environment represents a major challenge for health care worldwide. Carbapene-mases are carbapenem-hydrolysing enzymes that confer resistance to these "last-line" antibiotics having a direct im-pact on the limited treatment options available. In Argentina, carbapenemases NDM-like (New DelhiMetallo-ß-lactamase, MßL) have emerged in 2013. This resistance has increased in frequency and it has disseminated around the world at unprecedented levels.Objective:report the first isolation of a NDM-producing En-terobacteriaceae in our hospital.Materials and methods: the isolate analysed in this study was recovered from a bone biopsy belonging to an adult patient. The bacterial identification and antimicrobial sus-ceptibility testings were performed using conventional methods and the automated system Vitek 2C (Biomérieux). Phenotypic and molecular techniques were carried out for the detection and characterization of carbapenemases.Results: it was confirmed that the isolate, identified as Citro-bacter freundii, produces the NDM enzyme. It showed sensi-bility to aztreonam, colistin and fosfomicyn. Extended-spec-trum beta-lactamases were not detected.Discussion: in this study we report the first isolation of NDM-like MßL in our institution, a multirresistant pathogen associ-ated with a lack of effective antimicrobial treatment options. Given the high risk of these infections, an active search of mechanisms of resistance is mandatory. In addition, the establishment of accurate control measures is a must to attempt to overcome this formidable threat


Subject(s)
Male , Middle Aged , Citrobacter freundii , Diabetic Foot/complications , Enterobacteriaceae Infections/therapy , Carbapenem-Resistant Enterobacteriaceae/isolation & purification
3.
Braz. j. infect. dis ; 22(3): 235-238, May-June 2018. graf
Article in English | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-974217

ABSTRACT

ABSTRACT Herein we report a fatal case of donor-derived transmission of XDR-resistant carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) in cardiac transplantation. A 59-year-old male patient with non-obstructive hypertrophic cardiomyopathy underwent heart transplantation. On day 5 post-operation, blood cultures from the donor were positive for colistin-resistant carbapenemase-producing K. pneumoniae (ColR KPC-Kp) susceptible only to amikacin. Recipient blood cultures were also positive for ColR KPC-Kp with the same sensitivity profile as the donor isolate with an identical PFGE pattern. The patient was treated with double-carbapenems and amikacin. The patient evolved to pericarditis, osteomyelitis, and pulmonary necrosis, all fragment cultures positive for the same agent. The patient developed septic shock, multiple organ failure and died on day 50 post-transplantation. Based on current microbiological scenario worldwide the possibility of transmitting multidrug resistant (MDR) organisms should be considered.


Subject(s)
Humans , Male , Middle Aged , Tissue Donors , Klebsiella Infections/transmission , Heart Transplantation/adverse effects , Transplant Recipients , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Klebsiella pneumoniae/isolation & purification , Klebsiella Infections/drug therapy , Risk Factors , Colistin/pharmacology , Fatal Outcome , Drug Resistance, Multiple, Bacterial , Anti-Bacterial Agents/pharmacology
4.
Acta méd. costarric ; 60(2): 15-18, abr.-jun. 2018. graf
Article in Spanish | LILACS | ID: biblio-886408

ABSTRACT

Resumen Objetivo: determinar la frecuencia de metalo-β lactamasa tipo Nueva Delhi (NDM), en aislados de enterobacterias provenientes de pacientes hospitalizados con diferentes procesos infecciosos. Método: se realizó una investigación descriptiva transversal, agosto 2015 - octubre 2016, en el Hospital Alemán Nicaragüense. Se estudiaron 249 cepas en vigilancia activa a los carbapenémicos. La identificación y perfil de resistencia se efectuó en Vitek2; la sospecha de resistencia a los carbapenémicos se tomó cuando la CMI de Imipenem y Meropenem 2-4 μg/mL y Ertapenem 2 μg/mL, se determinó mediante Kirby Bauer, el test de sinergia triple disco (carbapenémicos y EDTA 10µg); se hizo la reacción en cadena de la polimerasa para metalo-β-lactamasa Nueva Delhi. Resultados: se analizaron 249 cepas, entre estas se identificó 45 cepas resistentes a los carbapenémicos, correspondiendo al 18%. De estas cepas, 43 dieron positivo para el test de sinergia con EDTA; 21 portaban el gen de Nueva Delhi. El 66% de metalo-β-lactamasa Nueva Delhi se encontró en aislamientos de Klebsiella pneumoniae, seguida de Escherichia vulneris en un 14%, Escherichia coli en un 5%, Providencia rettgeri en un 5%, Pantoea agglomerans en un 5% y Kluyvera cryocrescens en un 5%.19 Conclusiones: el hallazgo del presente estudio es una advertencia clara sobre la circulación de cepas de metalo-β-lactamasa tipo Nueva Delhi que codifican la resistencia a los carbapenémicos en el hospital analizado.


Abstract Objective: to determine the frequency of New Delhi-type metallo-β-lactamase (NDM) in isolates of enterobacteria from patients hospitalized with different infectious processes. Method: a cross-sectional descriptive study was carried out between August 2015 and October 2016 at Alemán Nicaragüense Hospital. A total of 249 strains were studied in active surveillance of carbapenems resistance. The identification and resistance profile was carried out in Vitek2. Suspected resistance to carbapenems was considered when the MIC of Imipenem and Meropenem was 2-4 μg/mL and for Ertapenem of 2 μg/mL, determined by Kirby Bauer, the triple disc synergy test (carbapenems and EDTA 10μg). A polymerase chain reaction test was made to determinate New Delhi metallo-β lactamase. Results: a total of 249 strains were analyzed, among which 45 strains resistant to carbapenems were identified, corresponding to 18%. Of these strains, 43 were positive for the synergy test with EDTA; 21 carried the New Delhi gene. Of the New Delhi metallo-β lactamase. 66% were found in isolates of Klebsiella pneumoniae, followed by Escherichia vulneris in 6 isolates, Escherichia coli in 2, Providencia rettgeri in 2, Pantoea agglomerans in 2 and Kluyvera cryocrescens by 2. Conclusions: the results of the present study are a clear warning about the circulation of New Delhi-type metallo-β-lactamase strains that codify for the resistance to carbapenems in the hospital analyzed.


Subject(s)
Humans , beta-Lactamase Inhibitors/isolation & purification , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Nicaragua
5.
Rev. chil. infectol ; 35(3): 253-261, 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-959439

ABSTRACT

Resumen Introducción: Las Enterobacteriaceae productoras de carbapenemasas (EPC) han tomado gran importancia en salud pública a una escala global, haciendo necesario implementar test rápidos para su detección oportuna. Objetivo: Evaluar tres metodologías para el tamizaje de EPC en hisopados rectales. Materiales y Métodos: Estudio prospectivo transversal. Se evaluaron 73 hisopados rectales por tres metodologías. Se realizó identificación y evaluación de susceptibilidad por sistemas automatizados y la producción de carbapenemasas se confirmó por test de Hodge modificado, sinergia con ácido borónico y EDTA. Resultados: Método 1 (ChromID CARBA®): detectó 20 muestras positivas (27,4%), 5 falsos positivos (6,9%), con índice de concordancia de 93,2%, sensibilidad 100% y especificidad de 90%. Método 2 (HB&L Carbapenemase®): detectó 17 muestras positivas (23,3%) y 3 falsos negativos (4,1%). La sensibilidad y especificidad fue 85 y 100% respectivamente, con concordancia de 95,9%. Método 3 (Xpert Carba-R®): detectó 19 muestras positivas (57,5 %) y 1 falso negativo (3,1%), sensibilidad 95%, especificidad 100% e índice de concordancia de 97%. Discusión: Existe amplia variedad de metodologías para búsqueda y detección rápida de microorganismos productores de carbapenemasas. La elección del método debe tener como requisito una buena sensibilidad y especificidad, rapidez y costo efectividad.


Background: Carbapenemase-producing Enterobacteriaceae (CPE) have taken great importance on public health at global scale, which makes it necessary to implement rapid test for its prompt detection. Aim: To evaluate three screening methods to detect CPE in rectal swabs. Material and Methods: Transverse study, prospective. Seventy three rectal swabs were evaluated by three methodologies. Microorganism identification and susceptibility testing were made using automated systems. Carbapenemase production was confirmed by modified Hodge test and synergy tests using boronic acid and EDTA. Results: The method 1 (ChromID CARBA®) detected 20 positive samples (27.4%), 5 false positives (6.9 %), with concordance index of 93.2%, sensitivity 100% and specificity of 90%. Method 2 (HB&L Carbapenemase®) detected 17 positive samples (23.3%) and 3 false negatives (4.1%). The sensitivity and specificity of the assay were 85% and 100%, with concordance index of 95.9%. Method 3 (Xpert Carba-R®) detected 19 positive samples (57.5%) and 1 false negatives (3.1%), sensitivity 95%, specificity 100% and concordance index of 97%. Discussion: There is a wide variety of methodologies for rapid detection of carbapenemase-producing microorganisms. Choosing the best method must have as requirement a good sensitivity, specificity, and cost-effectiveness.


Subject(s)
Humans , Rectum/microbiology , Mass Screening/methods , Bacteriological Techniques/methods , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/microbiology , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Cross-Sectional Studies , Prospective Studies , Sensitivity and Specificity
6.
Rev. Soc. Bras. Med. Trop ; 50(5): 685-688, Sept.-Oct. 2017. tab
Article in English | LILACS | ID: biblio-1041426

ABSTRACT

Abstract INTRODUCTION: The rapid global spread of carbapenem-resistant Enterobacteriaceae (CRE) is a threat to the health system. METHODS: We evaluated the antimicrobial susceptibility profiles of 70 CRE isolated in a tertiary hospital in Brazil between August and December 2015, and determined their resistance mechanisms. RESULTS: The most prevalent microorganism was Klebsiella pneumoniae (95.7%); it showed high-level resistance to carbapenems (>98%), with sensitivity to colistin (91.4%) and amikacin (98.6%). The bla KPC gene was detected in 80% of the CRE isolates. CONCLUSIONS: Evaluation of bacterial resistance contributes to an appropriate treatment, and the reduction of morbimortality and dissemination of resistance.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Young Adult , Enterobacteriaceae Infections/epidemiology , Tertiary Care Centers/statistics & numerical data , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Brazil/epidemiology , Microbial Sensitivity Tests , Polymerase Chain Reaction , Cross Infection/epidemiology , Enterobacter cloacae/isolation & purification , Citrobacter freundii/isolation & purification , Enterobacteriaceae Infections/microbiology , Escherichia coli/isolation & purification , Genotype , Klebsiella pneumoniae/isolation & purification , Anti-Infective Agents/pharmacology , Middle Aged
7.
Rev. Nac. (Itauguá) ; 8(2): 19-33, dic 2016.
Article in Spanish | LILACS, BDNPAR | ID: biblio-884750

ABSTRACT

Introducción: Serratia marcescens, bacilo Gram negativo, familia enterobacteriaceae; se encuentra en la flora intestinal del hombre y animales, en el medio ambiente y en reservorios como agua, cañerías, llaves, en insumos hospitalarios como jabones y antisépticos. Objetivos: determinar la presencia de un brote, localizaciones, comorbilidades presentes; serotipo del agente causal, cortar la cadena de transmisión. Metodología: estudio descriptivo de un brote epidémico por S. marcescens en el periodo comprendido entre 27 de Abril del 2015 a 19 de Junio del 2015. Se definió como caso a cualquier paciente con cultivo positivo para S. marcescens durante el período epidémico, ya que no se había identificado ningún cultivo positivo para esta bacteria con dicha resistencia en los años previos de vigilancia. Hipótesis: Transmisión por contacto, mano portada. Resultados durante el período epidémico se identificaron 5 pacientes con cultivos positivos para S. marcescens. Las comorbilidades fueron, choque séptico de origen enteral 1/5, cardiopatía/ bronquiolitis 1/5, pos operado de hemorragia ventricular 1/5, oclusión intestinal/ sepsis neonatal tardia1/5. Con procedimientos invasivos tales como, asistencia respiratoria mecánica, catéter venoso central, catéter urinario 5/5, cirugía 2/5, catéter de derivación externa 1/5, antibiótico de amplio espectro con 2 o más asociaciones 4/5, promedio de 43 DDI. Localizaciones: S. Traqueal 3/5, PC 2/5, liq. Peritoneal, HMC 1/5. Tasa de ataque 9.4%(5/53), letalidad 60%(3/5) Intervenciones: precauciones de contacto, cohorte, higiene hospitalaria. Conclusiones: brote a Serratia marcescens, productora de carbapenemasa, detectada mediante vigilancia activa en UCIP, más frecuentemente aislado en S. traqueal y PC. Se controló con medidas de prevención y control.


Introduction: Serratia marcescens, Gram negative bacillus, family enterobacteriaceae; Is found in the intestinal flora of man and animals, in the environment and in reservoirs such as water, pipes, keys, in hospital supplies such as soaps and antiseptics. Objectives: to determine the presence of an outbreak, localizations, present comorbidities; Serotype of the causative agent, cut the transmission chain. Methodology: a descriptive study of an outbreak of S. marcescens in the period from April 27, 2015 to June 19, 2015. Any patient with positive culture for S. marcescens during the epidemic period was defined as the case, since No positive culture for this bacterium had been identified with such resistance in previous years of surveillance. Hypothesis: Transmission by contact, hand cover. Results: 5 patients with S. marcescens positive cultures were identified during the epidemic period. Comorbidities were septic shock of enteral origin 1/5, heart disease / bronchiolitis 1/5, postoperative of ventricular hemorrhage 1/5, intestinal occlusion / late neonatal sepsis1 / 5. With invasive procedures such as mechanical ventilation, central venous catheter, urinary catheter 5/5, surgery 2/5, external lead catheter 1/5, broad spectrum antibiotic with 2 or more associations 4/5, average of 43 DDI . Locations: S. Traqueal 3/5, PC 2/5, liq. Peritoneal, HMC 1/5. Attack rate 9.4% (5/53), lethality 60% (3/5) Interventions: contact precautions, cohort, hospital hygiene. Conclusions: outbreak of Serratia marcescens, a producer of carbapenemase, detected by active surveillance in PICU, most frequently isolated in S. tracheal and PC. It was controlled with prevention and control measures.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Serratia marcescens/isolation & purification , Intensive Care Units, Pediatric , Cross Infection/epidemiology , Disease Outbreaks , Serratia Infections/epidemiology , Carbapenem-Resistant Enterobacteriaceae/isolation & purification , Paraguay/epidemiology , Peritonitis , Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Serratia Infections/prevention & control , Pneumonia, Ventilator-Associated
SELECTION OF CITATIONS
SEARCH DETAIL